Abstract:Background: PBRM1 gene abnormalities were recently found to play a role in tumor development and tumor immune activity. This article will explore the clinicopathological and molecular changes and tumor immune activity of the abnormal SWI/SNF complex subunit PBRM1 in gastric adenocarcinoma (GAC) and its significance.Methods: The cBioPortal, LinkedOmics and TISIDB datasets were used to analyze the abnormality of the PBRM1 gene in GAC and its relationship with prognosis, related molecular changes and tumor-infiltrating lymphocytes (TILs). In addition, 198 GAC cases were collected to further study the relationship between the loss/attenuation of PBRM1 expression and clinicopathology, prognosis, microsatellite stability, PD-L1 expression and TIL in GAC. DNA whole-exome sequencing was performed on 7 cases of gastric cancer with loss of PBRM1 expression.Results: The cBioPortal data showed that PBRM1 deletion/mutation accounted for 7.32% of GAC and was significantly associated with several molecular changes, such as molecular subtypes of GAC. The LinkedOmics dataset showed that PBRM1 mutation and its promoter DNA methylation showed lower PBRM1 mRNA expression, and PBRM1 mutation cases showed significantly higher mRNA expression of PD-L1 (CD274). TISIDB data showed that PBRM1 abnormalities were significantly positively associated with multiple TILs. In our group of 198 cases, the loss/attenuation of PBRM1 expression was significantly positively correlated with intra-tumoral tumor infiltrating lymphocytes (iTILs) and deficient MMR and PD-L1 expression. Kaplan-Meier survival analysis showed that the overall survival of GAC patients with loss/attenuation of PBRM1 expression was significantly better (p = 0.023). iTIL was an independent prognostic factor of GAC. Loss of PBRM1 expression often co-occurs with mutations in other SWI/SNF complex subunit genes, and there are some repetitive KEGG signaling changes.Conclusion: Abnormality of the PBRM1 gene may be related to the occurrence of some GACs and can affect tumor immune activity, thereby affecting clinicopathology and prognosis. It may be a potentially effective predictive marker for immunotherapy and a novel therapeutic approach associated with synthetic lethality.

PBAF loss leads to DNA damage-induced inflammatory signaling through defective G2/M checkpoint maintenance

PBRM1-deficient PBAF complexes target aberrant genomic loci to activate the NF-κB pathway in clear cell renal cell carcinoma

Abstract PR003: PBRM1-deficient PBAF complexes target aberrant genomic loci to activate NF-κB pathway in clear cell renal cell carcinoma

Mutational Analysis of PBRM1 and Significance of PBRM1 Mutation in Anti-PD-1 Immunotherapy of Clear Cell Renal Cell Carcinoma

Abstract 1494: PBRM1-deficient PBAF complexes target de novo genomic loci to activate NF-κB pathway in clear cell renal cell carcinoma

Comprehensive Analyses of PBRM1 in Multiple Cancer Types and Its Association with Clinical Response to Immunotherapy and Immune Infiltrates.

<i>PBRM1</i> deficiency oncogenic addiction is associated with activated AKT-mTOR signalling and aerobic glycolysis in clear cell renal cell carcinoma cells

Potential Roles of PBRM1 on Immune Infiltration in Cholangiocarcinoma.

PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer

PBRM1 loss is associated with increased sensitivity to MCL1 and CDK9 inhibition in clear cell renal cancer

Clinicopathological Significance, Related Molecular Changes and Tumor Immune Response Analysis of the Abnormal SWI/SNF Complex Subunit PBRM1 in Gastric Adenocarcinoma.

Evaluation of PD-L1 expression in PBRM1-altered clear cell renal cell carcinoma

PBRM1 Regulates Proliferation and the Cell Cycle in Renal Cell Carcinoma Through a Chemokine/chemokine Receptor Interaction Pathway

Development and validation of a <i>PBRM1</i>-associated immune prognostic model for clear cell renal cell carcinoma

CDC20‐Mediated Selective Autophagy Degradation of PBRM1 Affects Immunotherapy for Renal Cell Carcinoma

PBRM1 and the Glycosylphosphatidylinositol Biosynthetic Pathway Promote Tumor Killing Mediated by MHC-unrestricted Cytotoxic Lymphocytes.

Loss of KDM6A-mediated genomic instability and metabolic reprogramming differentially regulates responses to immune checkpoint therapy and chemotherapy in bladder cancer.

PBRM1 Mutation and Preliminary Response to Immune Checkpoint Blockade Treatment in Non-Small Cell Lung Cancer.

PD-1 blockade in tumors with mismatch repair deficiency.

53BP1 loss elicits cGAS-STING-dependent antitumor immunity in ovarian and pancreatic cancer

B-MYB is required for recovery from the DNA damage-induced G2 checkpoint in p53 mutant cells